A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents and Young Adults Treated With Glucocorticoids

Trial Profile

A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents and Young Adults Treated With Glucocorticoids

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Odanacatib (Primary)
  • Indications Corticosteroid-induced osteoporosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Sep 2016 Status changed from recruiting to discontinued.
    • 14 Aug 2015 According to the the ClinicalTrials.gov record, planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.
    • 27 Apr 2015 Planned End Date changed from 1 May 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top